Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
Top Page
Cumberland Pharmaceuticals
(NASDAQ:CPIX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.00
▼(-36.44% Downside)
Action:ReiteratedDate:03/07/26
CPIX scores as a cautious hold: improving fundamentals (deleveraging and a return to positive operating/free cash flow) and a constructive strategic/regulatory backdrop (Talicia JV, ifetroban Fast Track) are tempered by continued net losses/negative ROE and clearly bearish technical conditions (trading below key moving averages with weak momentum).
Positive Factors
Leverage reduction / stronger balance sheet
Material debt reduction materially lowers financial leverage and interest burden, improving solvency and flexibility. A leaner balance sheet supports sustained investment in commercialization and trials, reduces refinancing risk, and strengthens resilience through business cycles.
Negative Factors
Persistent net losses and negative ROE
Ongoing accounting losses and negative returns on equity show the company has not yet converted strong product-level margins into sustained profitability. Continued losses can erode equity, constrain reinvestment, and pressure long-term shareholder returns absent durable margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Leverage reduction / stronger balance sheet
Material debt reduction materially lowers financial leverage and interest burden, improving solvency and flexibility. A leaner balance sheet supports sustained investment in commercialization and trials, reduces refinancing risk, and strengthens resilience through business cycles.
Read all positive factors
Cumberland Pharmaceuticals (CPIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.37M
Dividend YieldN/A
Average Volume (3M)27.29K
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue Growth12.21%
EPS Growth69.91%
CountryUS
Employees91
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.09
Shares Outstanding14,956,627
10 Day Avg. Volume30,352
30 Day Avg. Volume27,288
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.39
Price to Sales (P/S)1.34
P/FCF Ratio12.31
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.01
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda16.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cumberland Pharmaceuticals Business Overview & Revenue Model
Company Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States...
How the Company Makes Money
Cumberland primarily makes money by selling its branded prescription pharmaceuticals. Revenue is generated from product sales to customers such as wholesalers and distributors (and, depending on the product and channel, hospitals, specialty pharma...
Cumberland Pharmaceuticals Key Performance Indicators (KPIs)
Cumberland Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strategic partnerships and international expansion, alongside strong revenue growth and clinical progress, which were slightly offset by shipment delays and increased competition. Overall, the sentiment of the call was positive, with more highlights than lowlights.Positive Updates
Strategic Partnership with RedHill Biopharma
Cumberland entered into a partnership with RedHill Biopharma to commercialize Talicia, an FDA-approved treatment for helicobacter pylori infections, showing a high eradication rate exceeding 90%.
Negative Updates
Product Shipment Delays
Third quarter sales were impacted by a delay in Kristalose and Caldolor shipments.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Partnership with RedHill Biopharma
Cumberland entered into a partnership with RedHill Biopharma to commercialize Talicia, an FDA-approved treatment for helicobacter pylori infections, showing a high eradication rate exceeding 90%.
Read all positive updates
Company Guidance
During Cumberland Pharmaceuticals' third-quarter 2025 financial call, the company announced several key developments. They reported $8.3 million in combined revenues for their FDA-approved brands during the quarter, with year-to-date revenues reaching $30.9 million, marking a 12% increase over the same period last year. Cumberland introduced Talicia, a new addition to their commercial product portfolio, aimed at treating helicobacter pylori infections, with U.S. net sales totaling $8 million in 2024. They formed a joint venture with RedHill Biopharma to commercialize Talicia in the U.S., investing $4 million over two years and sharing net revenues equally. The company achieved international milestones with the launch of Vibativ in Saudi Arabia and regulatory approval of ibuprofen injection in Mexico. Cumberland also highlighted ongoing clinical programs, with ifetroban being evaluated in several trials, including Duchenne muscular dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis. Financially, they recorded a third-quarter adjusted loss of $0.8 million or $0.06 per share, but year-to-date adjusted earnings reached $1.9 million or $0.13 per share. Cumberland ended the quarter with $66 million in total assets, including $15 million in cash, and has reduced total debt by $10 million since the end of 2024.Cumberland Pharmaceuticals Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
55
Neutral
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 44.52M | 37.87M | 39.55M | 42.01M | 35.99M |
| Gross Profit | 37.85M | 31.28M | 33.49M | 32.89M | 27.17M |
| EBITDA | 2.49M | 182.42K | 2.49M | 332.92K | -857.83K |
| Net Income | -2.84M | -6.48M | -6.28M | -5.57M | -3.51M |
Balance Sheet | |||||
| Total Assets | 76.82M | 75.58M | 81.78M | 92.93M | 84.46M |
| Cash, Cash Equivalents and Short-Term Investments | 11.44M | 17.96M | 18.32M | 19.76M | 27.04M |
| Total Debt | 10.18M | 20.57M | 18.43M | 20.96M | 16.06M |
| Total Liabilities | 52.28M | 53.04M | 52.52M | 56.95M | 41.86M |
| Stockholders Equity | 24.88M | 22.85M | 29.60M | 36.27M | 42.81M |
Cash Flow | |||||
| Free Cash Flow | 4.83M | -791.90K | 5.64M | 6.38M | 5.99M |
| Operating Cash Flow | 4.93M | -612.19K | 6.09M | 8.45M | 6.34M |
| Investing Cash Flow | -4.71M | 57.84K | -105.69K | -13.67M | -501.89K |
| Financing Cash Flow | -6.75M | 196.90K | -7.42M | -2.06M | -3.55M |
Cumberland Pharmaceuticals Technical Analysis
Neutral
4.72
Price Trends
3.67
Negative
3.42
Negative
3.41
Negative
Market Momentum
-0.17
Negative
46.89
Neutral
36.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Neutral. The current price of 4.72 is above the 20-day moving average (MA) of 3.16, above the 50-day MA of 3.67, and above the 200-day MA of 3.41, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 46.89 is Neutral, neither overbought nor oversold. The STOCH value of 36.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPIX.
Cumberland Pharmaceuticals Risk Analysis
Cumberland Pharmaceuticals disclosed 1 risk factors in its most recent earnings report. Cumberland Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cumberland Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $39.67M | -3.67 | -19.05% | ― | -65.77% | 38.61% | |
54 Neutral | $36.77M | -5.64 | -15.64% | ― | -23.60% | -179.33% | |
52 Neutral | $46.37M | -20.99 | -10.54% | ― | 12.21% | 69.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $128.13M | -1.97 | -29.39% | ― | 9.21% | 58.12% | |
49 Neutral | $35.36M | -4.80 | -199.09% | ― | -86.05% | 24.17% | |
40 Underperform | $148.55M | -0.36 | -2323.94% | ― | ― | 52.39% |
* Healthcare Sector Average
CPIX
Cumberland Pharmaceuticals
3.10
-1.18
-27.57%
ASRT
Assertio Therapeutics
19.88
9.79
97.03%
RMTI
Rockwell Med
0.93
-0.19
-16.70%
SCYX
SCYNEXIS
0.89
-0.06
-6.53%
KALA
KALA BIO
0.16
-4.61
-96.58%
IXHL
Incannex Healthcare Limited Sponsored ADR
2.96
-16.33
-84.66%
Cumberland Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cumberland Pharmaceuticals Wins Fast Track for Ifetroban
Positive
Feb 4, 2026
On February 4, 2026, Cumberland Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track Designation to its oral thromboxane receptor antagonist ifetroban, which targets a fatal form of heart disease in Duchenne musc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.